Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
BEIJING TIDE PHARMACEUTICAL CO., LTD. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 4 examiners and 4 art units, giving each recorded matter its own examiner and technical-group assignment. Docket management should therefore track prosecution developments at the individual application level.
WELLS, LAUREN QUINLAN is the busiest examiner, with 1 pending matter. The available data does not identify a concentrated examiner relationship, so counsel should not assume that one response approach will carry across the portfolio.
Consistent treatment of recurring technology and claim issues remains useful, particularly for disclosure support and amendment policy. Each matter should nevertheless receive separate analysis of the assigned examiner, art unit, cited prior art, and procedural posture.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
| ARNOLD, ERNST V | 1 | 48.2% | +12.8% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +36.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18856731 | EGFR DEGRADATION AGENT | WELLS, LAUREN QUINLAN | — |
| 18710713 | NANOCRYSTALLINE PREPARATION OF ROCK2 INHIBITOR AND PREPARATION METHOD THEREFOR | ARNOLD, ERNST V | — |
| 17607438 | METHOD FOR TREATING COUGH BY USING DIAMINOPYRIMIDINE COMPOUND | PECKHAM, RICHARD GRANT | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1613 | 1 |
| 1623 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18856731 | EGFR DEGRADATION AGENT | WELLS, LAUREN QUINLAN | 1622 | §102§103§112DP | Non-Final OA | — | Pending | Oct 14, 2024 |
| 18710713 | NANOCRYSTALLINE PREPARATION OF ROCK2 INHIBITOR AND PREPARATION METHOD THEREFOR | ARNOLD, ERNST V | 1613 | §103DP | Non-Final OA | — | Pending | May 16, 2024 |
| 17637690 | COMPOUND INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK | SHTERENGARTS, SAMANTHA L | 1623 | §112 | Non-Final OA | 14d | Pending | Feb 23, 2022 |
| 17607438 | METHOD FOR TREATING COUGH BY USING DIAMINOPYRIMIDINE COMPOUND | PECKHAM, RICHARD GRANT | 1627 | — | Final Rejection | — | Pending | Oct 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBEIJING TIDE PHARMACEUTICAL CO., LTD. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Lauren Quinlan Wells has the most, with 1 of BEIJING TIDE PHARMACEUTICAL CO., LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
